Vaccitech (NASDAQ:VACC) Trading Down 0.4%

Shares of Vaccitech plc (NASDAQ:VACC) were down 0.4% during trading on Wednesday . The stock traded as low as $1.34 and last traded at $1.36. Approximately 10,315 shares traded hands during mid-day trading, a decline of 96% from the average daily volume of 244,643 shares. The stock had previously closed at $1.36.

Vaccitech Stock Performance

The company has a market cap of $53.39 million, a price-to-earnings ratio of -0.97 and a beta of -0.40. The company’s 50 day moving average price is $2.14 and its 200 day moving average price is $2.68.

Hedge Funds Weigh In On Vaccitech

An institutional investor recently bought a new position in Vaccitech stock. M&G Plc purchased a new position in shares of Vaccitech plc (NASDAQ:VACC) in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 5,197,349 shares of the company’s stock, valued at approximately $25,987,000. M&G Plc owned approximately 13.48% of Vaccitech as of its most recent filing with the SEC. Hedge funds and other institutional investors own 26.13% of the company’s stock.

Vaccitech Company Profile

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer.